Phaseline

Companies › Ocusun Ophthalmic Pharmaceutical (Guangzhou)

Ocusun Ophthalmic Pharmaceutical (Guangzhou): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZOC2017217–Phase 2Age Related CataractsFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07395986ZOC2017217Phase 2Age Related CataractsOphthalmologyFeb 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Caravel Oculus

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.